A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice
- 8 October 2001
- Vol. 39 (12) , 1815-1820
- https://doi.org/10.1016/s0041-0101(01)00101-5
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Preclinical update on BOTOX® (botulinum toxin type A)‐purified neurotoxin complex relative to other botulinurn neurotoxin preparationsEuropean Journal of Neurology, 1999
- Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A–resistant cervical dystoniaNeurology, 1999
- Botulinum toxin: Chemistry, pharmacology, toxicity, and immunologyMuscle & Nerve, 1997
- Response to botulinum toxin F in seronegative botulinum toxin A—resistant patientsMovement Disorders, 1996
- Botulinum toxin A for spasticity, muscle spasms, and rigidityNeurology, 1995
- Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm.Journal of Neurology, Neurosurgery & Psychiatry, 1990
- Botulinum toxin injections for cervical dystoniaNeurology, 1990
- Botulinum A toxin for cranial‐cervical dystoniaNeurology, 1987
- Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves.The Journal of cell biology, 1986
- Ocular Involvement in Benign Botulism BAmerican Journal of Ophthalmology, 1975